Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD hospital infection settlement

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...

You may also be interested in...



Dispute Arises Over Hospital-Acquired Infection Tests

French diagnostic firm BioMérieux is attempting to renege on a licensing agreement with Becton Dickinson relating to methods for detecting one of the most common infections picked up in hospitals, according to BD

Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

Wave Of Launches Boosts US Biosimilars Market

A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.

UsernamePublicRestriction

Register

MT025118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel